TRIPLE NEGATIVE BREAST CANCER

This study tests a new oral liquid called BLEX 404 combined with the chemotherapy drug Docetaxel in people with advanced triple negative breast cancer. The goal is to find a safe dose and see if the combination helps shrink tumors. About 44 women aged 20-70 will take part.

This study tests whether injecting the anesthetic levobupivacaine around the tumor and nearby nerves during breast-conserving surgery can reduce the risk of cancer returning in women with triple-negative breast cancer. About 760 women who have already had chemotherapy will be ran…

This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard post-surgery treatment can prevent breast cancer from returning in people with early-stage triple-negative breast cancer who still had cancer after initial chemo and pembrolizumab. About 1000…

This study compares gemcitabine to the standard drug paclitaxel as first treatment for Black Caribbean women with metastatic triple-negative breast cancer. 750 women from Jamaica, Trinidad, and Barbados will receive one of the two drugs by injection. The goal is to see which drug…

This study tests whether a three-drug combination can help people with triple-negative breast cancer whose tumors stopped responding to immunotherapy. About 46 women will receive cromolyn, TQB2102, and panpulimab to see if the cancer shrinks or stabilizes. The goal is to control …

This study tests whether using special dosing guidelines for people with the Duffy null blood type can reduce or delay the need to lower or pause their cancer drugs, and lower the risk of fever from low white blood cells. It includes 90 adults with multiple myeloma or triple-nega…

This study looks at whether women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely avoid breast and lymph node surgery. About 150 participants will be randomly assigned to either standard care with surgery or the same care without …

This early-phase trial tests a new drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (prostate, lung, breast, or other solid tumors) that have not responded to standard treatments. The study has two parts: first, finding the safest dose, then checking…

This study tests a drug called ARX788 for people with HER2-low breast cancer that has spread or cannot be removed by surgery. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The trial will enroll 36 adults to see if the d…

This study tests whether some people with early-stage breast cancer can safely avoid surgery after chemotherapy and radiation. Participants will be monitored with MRIs, mammograms, and blood tests to check if the cancer stays away. The goal is to see if a non-surgical approach wo…

This early-phase trial tests a new approach for triple negative breast cancer, a high-risk type. It combines cryoablation (freezing the tumor) with immune checkpoint inhibitors to help the body's immune system recognize and attack cancer cells. The study will enroll 36 women with…

This early-phase study tests a personalized cancer vaccine (PCI) alone or with an immune-boosting drug (AB248) in 30 people newly diagnosed with triple negative breast cancer. The vaccine is custom-made from each patient's tumor. The main goal is to see if the approach is safe an…

This early-phase study tests a new treatment called GCAR1, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells that carry a specific marker (GPNMB). The study enrolls up to 30 adults in Canada with advanced alveolar so…

This study tests a personalized approach for people with stage II or III triple-negative breast cancer. Participants first receive 12 weeks of standard chemo plus the immunotherapy pembrolizumab. Those whose tumors shrink well stop treatment early; others are randomly assigned to…

This study is testing an artificial intelligence (AI) tool designed to help doctors treat triple-negative breast cancer. The AI analyzes images of a patient's tumor tissue to predict how well they might respond to chemotherapy and their long-term survival chances. The research wi…

This study tests whether regular blood tests (ctDNA) can detect the return of triple-negative breast cancer earlier than standard follow-up. Thirty participants who finished treatment will be randomly assigned to usual care or usual care plus blood tests. The goal is to see if th…